A new cancer treatment protocol involving repurposed drugs Ivermectin, Fenbendazole, and Mebendazole has recently passed peer review and is being heralded as a potential breakthrough in cancer therapy.

The science behind the application of Ivermectin along with Mebendazole in the potential treatment of cancer is compelling:

This strategy is based on the mitochondrial-stem cell connection (MSCC) theory, which posits that cancer originates from impaired mitochondrial function in stem cells, leading to the formation of highly tumorigenic cancer stem cells (CSCs).

These CSCs are believed to drive tumor recurrence and metastasis and exhibit resistance to conventional therapies.

According to the publication, ivermectin, fenbendazole, and mebendazole each exhibit anticancer properties through distinct yet complementary mechanisms. Ivermectin, an antiparasitic agent, induces apoptosis in cancer cells by modulating mitochondrial function and inhibiting critical pathways such as glycolysis. It has shown significant efficacy in shrinking tumor volumes in various cancer types, including pancreatic cancer, when used alone or in combination with other agents.